Table 3 Outcome of ART cycles in women with intramural fibroids and in a control group (without myoma), reporting ** significant and * non-significant results
Authors | Year | Type | Size (mm) | Myoma group | Control group | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
No. of patients | Implantation (%) | Pregnancy (%) | Abortion (%) | No. of patients | Implantation (%) | Pregnancy (%) | Abortion (%) | ||||
Stovall et al.[6]** | 1998 | Prospective IVF/ET and ZIFTb | 10-54 | 91 (SS 5, IM 86) | 46/334a (13.8%) | 34/91a (37.4%) | 4/34 (11.8%) | 91 | 65/330a (19.7%) | 48/91a (52.7%) | 4/48 (8.3%) |
Eldar-Geva et al.[5]** | 1998 | Retrospective IVF/ET and GIFTb | 23.7 ± 7.1 | 55 IM | NAa (6.4%) | 9/55a (16.4%) | 3/9 (33.3%) | 318 | NAa (15.8%) | 98/318a (30.8%) | 20/98 (20.4%) |
Hart et al.[20]** | 2001 | Prospective IVF/ICSI | ≤50 | 86 (IM or SS) | NAa (11.9%) | 20/86a (23.3%) | 4/20 (20.0%) | 290 | NAa (20.2%) | 99/290a (34.1%) | NA |
Surrey et al.[8]** | 2001 | Retrospective IVF/ET (Age <40 y) | 20 ± 2 | 51 IM | 36/168a (21.4%) | 27/51 (52.9%) | 2/27 (7.4%) | 257 | 265/796a (33.3%) | 166/268 (61.9%) | 12/166 (7.2%) |
Gianaroli et al.[21]** | 2005 | Retrospective IVF/ICSIb | 18 ± 14 | 75 IM | 48/267a (18.0%) | 45/129 (34.9%) | 18/45a (40.0%) | 127 | 63/238a (26.5%) | 53/129 (41.1%) | 10/53a (18.9%) |
Girgin et al.[22]* | 2005 | Retrospective IVF/ICSIb | 30-60 | 95 IM | NA | 26/95a (27.4%) | 2/26 (7.7%) | 100 | NA | 43/100a (43.0%) | 2/43 (4.7%) |
Khalaf et al.[17]** | 2006 | Prospective IVF/ICSI | 23 ± 11 | 112 (IM or SS) | NA | NAa (23.6%) | NA | 322 | NA | NAa (32.9%) | NA |
Farhi et al.[23]* | 1995 | Retrospective IVF/ETb | NA | 28 IM/SS mix | 31/471 (6.6%) | 25/86 (29.0%)b | 10/25 (40.0%) | 50 | 37/317 (11.7%) | 32/127 (25.2%)c | 8/32 (25.0%) |
Ramzy et al.[10]* | 1998 | Retrospective IVF/ICSI b | 3.2 ± 1.1 | 39 (SS 32, IM 12) | 16/128 (12.5%) | 15/39 (38.5%) | 3/15 (20.0%) | 367 | 165/1192 (13.8%) | 123/367 (33.5%) | 19/123 (15.5%) |
Dietterich et al.[11]* | 2000 | Retrospective IVFb (Age >35 y) | 10-20 | 9 (IM or SS) | NA (33.0%) | NA (56.0%) | NA | NA | NA (32.7%) | NA (64.0%) | NA |
Jun et al.[12]* | 2001 | Retrospective IVF | < 70 | 141 (IM or SS or SM) | NA | 43/141 (30.5%) | 8/43 (18.6%) | 406 | NA | 169/406 (41.6%) | 22/169 (13.0%) |
Yarali et al.[14]* | 2002 | Retrospective ICSI/ETb | 50-100 | 73 IM | 18/183 (9.8%) | 16/73 (21.9%) | 1/16 (6.2%) | 324 | 102/911 (11.2%) | 90/324 (27.8%) | 6/90 (6.6%) |
Ng et al.[13]* | 2002 | Prospective IVF/ET | 25-97.5 | 77 (SS or IM) | 22/159 (13.8%) | 20/77 (26.0%) | 4/20 (20.0%) | 312 | 62/638 (14.4%) | 74/312 (23.7%) | 6/74 (8.1%) |
Check et al.[17]* | 2002 | Prospective IVF/ETb | ≤ 50 | 61 (IM 32, SS plus IM 19) | 27/208 (13.6%) | 21/61 (34.4%) | 7/21 (33.3%) | 61 | 41/203 (20.2%) | 29/61 (47.5%) | 6/29 (20.7%) |
Oliveira et al.[17]* | 2004 | Retrospective IVF/ICSIb | < 70 | 130 IM | NA | 63/130 (48.5%) | 17/63 (27.0%) | 245 | NA | 110/245 (44.9%) | 31/110 (28.2%) |
Ballesteros et al.[24]* | 2006 | Retrospective IVF | < 50 | 65 cycle (IM or SS) | NA | NA (20.0%) | NA (46.1%) | 366 cycle | NA | NA (23.2%) | NA (29.4%) |
Klatsky et al.[25]* | 2007 | Retrospective IVF | 28d | 94 (IM, SS or IM plus SS) | NA (36%) | 44/94 (47.0%) | 8/44 (15.0%) | 275 | NA (36%) | 149/275 (54.0%) | 14/149 (9.0%) |
Bozdag et al.[26]* | 2009 | Retrospective ICSI | 5-43 | 61 IM | 33/162 (20%) | 22/61 (36%) | 6/22 (27%) | 444 | 250/1299 (19%) | 167/444 (38%) | 31/167 (19%) |
Somigliana et al.[27]* | 2011 | Prospective IVF/ICSI | 50 | 119 (IM or SS) | NA (17%) | 26/119 (22%) | 6/28 (21%) | 119 | NA (11%) | 22/119 (19%) | 6/22 (27%) |